Merck’s new spin-off to focus on infertility treatment
Merck Serono announced the creation of TocopheRx, a Boston-based spin-off company resulting from its Entrepreneur Partnership Program (EPP) launched in April 2012. TocopheRx, the 8th spin-off in the EPP will focus on the development of oral follicle-stimulating hormone (FSH) agonists for treatment of infertility, by advancing Merck Serono's preclinical program towards clinical testing. Merck Serono will initially invest $ 3.2 million (approx. € 2.4 million) in seed funding.
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.